Table IV.
Antitumor activity and body weight changes in mice implanted with human colorectal tumor SW48 after treatment with TAS-102 and panitumumab.
| Group | Dose (mg/kg) | Schedule | RTVa (mean ± SD) | TGIb (%) | RTV5c (days) | BWCd
|
|
|---|---|---|---|---|---|---|---|
| (Mean ± SD, g) | (%) | ||||||
| Control | – | – | 20.70±9.81 | 0 | 11.51±4.84 | 0.6±1.5- | 2.3 |
| TAS-102 | 150 | Day 1–14 (b.i.d.) | 12.33±3.86 NS | 40.5 | 16.40±2.37 NS | −1.8±1.6e | −7.1 |
| Panitumumab | 3 | Day 1, 5, 8, 12 | 13.86±4.94 NS | 33.1 | 15.59±4.33 NS | 0.3±1.1 NS | 1.0 |
| Combination | 150+3 | 7.15±2.34e | 65.5 | >23.85f,g | 0.7±1.0 NS | 2.8 | |
a
Relative tumor volume on day 29;
b
Tumor growth inhibition ratio on day 29;
c
The period, RTV reaches 5;
d
Body weight change from day 0 to day 29; Each group consists of 7 mice;
e
P<0.05 vs. control using the two-sided Aspin Welch t-test;
f
P<0.01 vs. control using the log-rank test;
g
P<0.01 vs. either monotherapy using the log-rank test; NS vs. control; BWC, body weight change; RTV, relative tumor volume; TGI, tumor growth inhibition; NS, not significant.